Extract
Dysanapsis refers to an anthropometric mismatch of airway tree calibre that was first inferred from inter-individual differences in maximum expiratory airflow among healthy adults [2] and later confirmed by direct measurement using computed tomography (CT) in community-based samples [3]. Variation in airway tree calibre is evident by early adulthood [4], extends to the peripheral airways (a major site of tobacco smoke-associated pathobiology) [5] and is associated with greater aerosol deposition in computational models [6].
Abstract
Dysanapsis – an anthropometric mismatch between airway tree calibre and lung size that is common in the general population – is strongly associated with all-cause mortality and increases susceptibility to tobacco smoking-related diseases https://bit.ly/42oDe8J
Acknowledgement
Thanks to James A. Hanley for his statistical guidance at the study design stage and his constructive feedback on the manuscript. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.
Footnotes
Author contributions: B.M. Smith had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: M. Vameghestahbanati and B.M. Smith. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: M. Vameghestahbanati and B.M. Smith. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: M. Vameghestahbanati, A. Benedetti and B.M. Smith.
Conflict of interest: C. Sack reports grants from NIEHS K23ES030725-04, outside the submitted work. E.A. Hoffman reports support for the present manuscript from NIH; E.A. Hoffman also reports that he is founder and shareholder of VIDA Diagnostics, and an unpaid member of Photon Counting CT advisory board for Siemens Healthineers, outside the submitted work. N.B. Allen reports support for the present manuscript from NIH/NHLBI; N.B. Allen also reports grants from NIH/NHLBI, outside the submitted work. J. Guo reports support for the present manuscript from National Institutes of Health; J. Guo also reports being a shareholder of VIDA Diagnostics, outside the submitted work. E.D. Michos reports advisory board participation with AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk and Pfizer, outside the submitted work. S.J. Shea reports support for the present manuscript from the National Heart, Lung, and Blood Institute. R.G. Barr reports support for the present manuscript from NIH, COPD Foundation and Foundation for the NIH; R.G. Barr also reports grants from American Lung Association, and advisory board participation with COPD Foundation, outside the submitted work. B.M. Smith reports support for the present manuscript from NIH, Canadian Lung Association, CIHR and Quebec Health Research Fund. All other authors have no potential conflicts of interest to disclose.
Support statement: This research was supported by R01-HL130506, R01-HL077612, R01-093081, R01-HL155816, R01-HL121270, K23ES030725, K25ES034064, contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, by grants UL1-TR-000040, UL1-TR-001079 and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS) and by the American Lung Association. M. Vameghestahbanati was supported by Vanier Canada Graduate Scholarship. The information contained herein was derived in part from data provided by the Bureau of Vital Statistics, New York City Department of Health, and Mental Hygiene. This publication was developed under STAR research assistance agreements, numbers RD831697 (MESA Air) and RD-83830001 (MESA Air Next Stage), awarded by the US Environmental Protection Agency. It has not been formally reviewed by the EPA. The views expressed in this document are solely those of the authors and the EPA does not endorse any products or commercial services mentioned in this publication. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received January 23, 2023.
- Accepted April 27, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
